IL17A and infection: Treatment of mice with GW9662 and anti-IL-17 abrogated the beneficial effects of GW9662 on weight loss and EAEC burden, suggesting that the blockade of PPAR γ ameliorates EAEC infection and disease through an IL-17-dependent mechanism.